Stem Cell Sciences plc (SCS, AIM:STEM, ASX:STC), the global biotechnology company focused on the commercialisation of stem cells and stem cell technologies in research and cell-based therapies, today announced the signing of an exclusive agreement with San Raffaele Scientific Institute (Milan, Italy) covering assay validation and future commercialisation of novel human muscle stem cells for drug discovery and toxicology applications. Financial terms were not disclosed.
